JAK2 mutational status or allele burden have been related to clinical signs of the disease like splenomegaly, transformation to Acute Myeloid Leukemia (AML) and overall survival [27–29], thus pointing to JAK2 inhibition as a promising strategy to treat MF. The gene discussed is JAK2; the disease is Splenomegaly.